10-Q quarterly report · filed Nov 12, 2026

Prime Medicine, Inc. (PRME) Q3 2026 10-Q Quarterly Report

Short answer

Prime Medicine, Inc. (PRME) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $6M (up 408.0% year over year) with net income of −$39M.

Q3 2026 key financials · XBRL

Revenue
$6M
+408.0% YoY
Net income
−$39M
+22.8% YoY · +7.3% QoQ
Operating margin
-641.6%
EPS (diluted)
−$0.22
+26.7% YoY · +4.3% QoQ

Source: XBRL data from the Prime Medicine, Inc. (PRME) Q3 2026 10-Q on SEC EDGAR. USD.

Prime Medicine, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue: not disclosed; no product sales, collaboration revenue only
  • R&D expenses $34.1M vs $44.0M YoY, down $9.9M
  • G&A expenses $10.0M vs $11.2M YoY, down $1.2M
  • Cash, equivalents and investments $61.2M at September 30, 2026, including restricted cash $74.8M
  • Operating cash outflow $120.4M for nine months, with $109.2M investment maturities; November offering added $134.7M net proceeds

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Risk factors remain updated through the June 30, 2026 Form 10-Q

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Prime Medicine, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.